Latest News and Press Releases
Want to stay updated on the latest news?
-
AUDUBON, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the results of the study “Clinical and radiographic...
-
AUDUBON, Pa., May 10, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today it is sponsoring the Society of Lateral Access Surgery’s...
-
AUDUBON, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the first quarter ended...
-
AUDUBON, Penn., April 17, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended...
-
AUDUBON, Pa., April 05, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the launch of two innovative lateral expandable...
-
AUDUBON, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, is pleased to announce its entry into the orthopedic trauma market....
-
AUDUBON, Pa., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year...
-
AUDUBON, Pa., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full...
-
AUDUBON, Pa., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth...
-
AUDUBON, Pa., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the results of its seven-year clinical trial follow-up...